RevOpsis Therapeutics is a privately held biopharmaceutical company founded in 2018 that focuses on next-generation ophthalmic treatments. Its proprietary Rev-Mod platform enables the creation of fully human, modular, multispecific biologics aimed at improving durability and efficacy in chronic eye disorders. The lead program, RO-104, is a first-in-class tri-specific molecule that simultaneously targets VEGF-A, VEGF-C, and Ang-2, the three dominant angiogenic pathways implicated in retinal vascular disease progression. Initial clinical targets include neovascular age-related macular degeneration and diabetic eye disease, large markets with significant unmet need. The company intends to advance RO-104 through preclinical studies and broaden its pipeline of ophthalmic assets using the new funding. No commercial revenue or patient usage metrics have been disclosed. RevOpsis is led by a team of physicians, scientists and business executives committed to introducing longer-lasting, more effective retinal therapies.

Total raised

$17M

Funding rounds

3

Latest round

Seed

Latest activity

Apr 2024